Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia th… Read more
Sun Pharma Advanced Research Company Limited (SPARC) - Net Assets
Latest net assets as of September 2025: ₹-3.45 Billion INR
Based on the latest financial reports, Sun Pharma Advanced Research Company Limited (SPARC) has net assets worth ₹-3.45 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹3.22 Billion) and total liabilities (₹6.67 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹-3.45 Billion |
| % of Total Assets | -106.89% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -825.52% |
| Growth Volatility | 536.98 |
Sun Pharma Advanced Research Company Limited - Net Assets Trend (2007–2025)
This chart illustrates how Sun Pharma Advanced Research Company Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sun Pharma Advanced Research Company Limited (2007–2025)
The table below shows the annual net assets of Sun Pharma Advanced Research Company Limited from 2007 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹-2.17 Billion | -272.52% |
| 2024-03-31 | ₹1.26 Billion | -75.48% |
| 2023-03-31 | ₹5.13 Billion | +1542.14% |
| 2022-03-31 | ₹312.26 Million | +118.56% |
| 2021-03-31 | ₹-1.68 Billion | -802.72% |
| 2020-03-31 | ₹-186.38 Million | -106.29% |
| 2019-03-31 | ₹2.96 Billion | +60.37% |
| 2018-03-31 | ₹1.85 Billion | +15.71% |
| 2017-03-31 | ₹1.60 Billion | +433.89% |
| 2016-03-31 | ₹299.03 Million | -70.04% |
| 2015-03-31 | ₹997.99 Million | -28.36% |
| 2014-03-31 | ₹1.39 Billion | +28.47% |
| 2013-03-31 | ₹1.08 Billion | +262.79% |
| 2012-03-31 | ₹-666.09 Million | -1284.47% |
| 2011-03-31 | ₹56.23 Million | -60.19% |
| 2010-03-31 | ₹141.24 Million | -60.41% |
| 2009-03-31 | ₹356.78 Million | -20.39% |
| 2008-03-31 | ₹448.18 Million | -9.82% |
| 2007-03-31 | ₹497.01 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sun Pharma Advanced Research Company Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2316617400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₹324.50 Million | % |
| Other Comprehensive Income | ₹340.45 Million | % |
| Other Components | ₹20.38 Billion | % |
| Total Equity | ₹-2.17 Billion | 100.00% |
Sun Pharma Advanced Research Company Limited Competitors by Market Cap
The table below lists competitors of Sun Pharma Advanced Research Company Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Wallix Group SA
PA:ALLIX
|
$121.09 Million |
|
Altinkilic Gida ve Sut Sanayi Ticaret A.S.
IS:ALKLC
|
$121.14 Million |
|
Copper 360 Ltd
JSE:CPR
|
$121.16 Million |
|
91App Inc
TWO:6741
|
$121.17 Million |
|
Wuhu Fuchun Dye and Weave Co.Ltd.
SHG:605189
|
$121.05 Million |
|
MNtech Co. Ltd
KQ:095500
|
$121.04 Million |
|
DOWAY
PINK:DOWAY
|
$121.01 Million |
|
Salmon Evolution Holding AS
OL:SALME
|
$121.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sun Pharma Advanced Research Company Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,257,554,000 to -2,169,500,000, a change of -3,427,054,000 (-272.5%).
- Net loss of 3,425,100,000 reduced equity.
- Other comprehensive income increased equity by 615,000.
- Other factors decreased equity by 2,569,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹-3.43 Billion | -157.88% |
| Other Comprehensive Income | ₹615.00K | +0.03% |
| Other Changes | ₹-2.57 Million | -0.12% |
| Total Change | ₹- | -272.52% |
Book Value vs Market Value Analysis
This analysis compares Sun Pharma Advanced Research Company Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-03-31 | ₹2.34 | ₹114.80 | x |
| 2008-03-31 | ₹2.11 | ₹114.80 | x |
| 2009-03-31 | ₹1.68 | ₹114.80 | x |
| 2010-03-31 | ₹0.67 | ₹114.80 | x |
| 2011-03-31 | ₹0.27 | ₹114.80 | x |
| 2012-03-31 | ₹-3.14 | ₹114.80 | x |
| 2013-03-31 | ₹4.94 | ₹114.80 | x |
| 2014-03-31 | ₹5.85 | ₹114.80 | x |
| 2015-03-31 | ₹4.22 | ₹114.80 | x |
| 2016-03-31 | ₹1.26 | ₹114.80 | x |
| 2017-03-31 | ₹6.49 | ₹114.80 | x |
| 2018-03-31 | ₹7.45 | ₹114.80 | x |
| 2019-03-31 | ₹11.59 | ₹114.80 | x |
| 2020-03-31 | ₹-0.71 | ₹114.80 | x |
| 2021-03-31 | ₹-6.42 | ₹114.80 | x |
| 2022-03-31 | ₹1.19 | ₹114.80 | x |
| 2023-03-31 | ₹18.01 | ₹114.80 | x |
| 2024-03-31 | ₹3.88 | ₹114.80 | x |
| 2025-03-31 | ₹-6.68 | ₹114.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sun Pharma Advanced Research Company Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -477.23%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-97.72%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -10.03% | -1607.26% | 0.01x | 1.11x | ₹-99.54 Million |
| 2008 | -10.89% | -13.03% | 0.61x | 1.37x | ₹-93.65 Million |
| 2009 | -25.62% | -26.01% | 0.57x | 1.73x | ₹-127.08 Million |
| 2010 | -152.60% | -62.64% | 0.48x | 5.11x | ₹-229.66 Million |
| 2011 | -151.16% | -14.57% | 0.75x | 13.78x | ₹-90.63 Million |
| 2012 | 0.00% | -249.28% | 0.34x | 0.00x | ₹-655.71 Million |
| 2013 | -20.75% | -25.77% | 0.42x | 1.93x | ₹-333.38 Million |
| 2014 | 21.77% | 18.15% | 0.91x | 1.32x | ₹163.94 Million |
| 2015 | -39.60% | -25.38% | 1.09x | 1.43x | ₹-495.00 Million |
| 2016 | -234.07% | -43.40% | 0.99x | 5.44x | ₹-729.82 Million |
| 2017 | -75.33% | -66.44% | 0.66x | 1.72x | ₹-1.36 Billion |
| 2018 | -106.64% | -251.73% | 0.25x | 1.67x | ₹-2.15 Billion |
| 2019 | -49.09% | -79.53% | 0.46x | 1.35x | ₹-1.75 Billion |
| 2020 | 0.00% | -406.70% | 0.28x | 0.00x | ₹-3.11 Billion |
| 2021 | 0.00% | -59.75% | 1.10x | 0.00x | ₹-1.34 Billion |
| 2022 | -651.37% | -148.19% | 0.49x | 8.97x | ₹-2.07 Billion |
| 2023 | -43.41% | -93.22% | 0.29x | 1.62x | ₹-2.74 Billion |
| 2024 | -307.91% | -512.56% | 0.15x | 4.10x | ₹-4.00 Billion |
| 2025 | 0.00% | -477.23% | 0.21x | 0.00x | ₹-3.21 Billion |
Industry Comparison
This section compares Sun Pharma Advanced Research Company Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sun Pharma Advanced Research Company Limited (SPARC) | ₹-3.45 Billion | -10.03% | N/A | $121.05 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |